Cambridge Heart, Inc. (OTC Bulletin Board: CAMH) has received clearance from the U.S. FDA to start marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module has been created to work with existing cardiac stress test platforms distributed by other manufacturers. The FDA 510 clearance enables Cambridge Heart to start the marketing of the module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc. (NASDAQ: CSCX).
Xplosive Stocks, an online financial publication, provides investors timely stock market information.
Sign Up Today for our Free Stock Newsletter
Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA).
Sign up for the free Xplosive Stocks newsletter. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by Xplosive Stocks can sign up for free by visiting our website.
About Us
Xplosive Stock is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We focus on Xplosive Stocks and track small cap companies that are on the brink of a financial breakout. To feature a company on our website please contact us at the email listed below.
Please click here to read the full disclaimer.
